- Home
- ESCA vs ADCT Comparison
ESCA vs ADCT Comparison
Compare ESCA & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESCA
- ADCT
- Stock Information
- Founded
- ESCA 1922
- ADCT 2011
- Country
- ESCA United States
- ADCT Switzerland
- Employees
- ESCA N/A
- ADCT N/A
- Industry
- ESCA Recreational Games/Products/Toys
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- ESCA Consumer Discretionary
- ADCT Health Care
- Exchange
- ESCA Nasdaq
- ADCT Nasdaq
- Market Cap
- ESCA 198.2M
- ADCT 224.3M
- IPO Year
- ESCA N/A
- ADCT 2020
- Fundamental
- Price
- ESCA $14.99
- ADCT $1.64
- Analyst Decision
- ESCA
- ADCT Strong Buy
- Analyst Count
- ESCA 0
- ADCT 5
- Target Price
- ESCA N/A
- ADCT $8.00
- AVG Volume (30 Days)
- ESCA 18.4K
- ADCT 543.8K
- Earning Date
- ESCA 03-31-2025
- ADCT 03-12-2025
- Dividend Yield
- ESCA 4.04%
- ADCT N/A
- EPS Growth
- ESCA 35.81
- ADCT N/A
- EPS
- ESCA 0.94
- ADCT N/A
- Revenue
- ESCA $253,074,000.00
- ADCT $70,717,000.00
- Revenue This Year
- ESCA N/A
- ADCT $6.81
- Revenue Next Year
- ESCA N/A
- ADCT $11.23
- P/E Ratio
- ESCA $15.52
- ADCT N/A
- Revenue Growth
- ESCA N/A
- ADCT N/A
- 52 Week Low
- ESCA $12.34
- ADCT $1.55
- 52 Week High
- ESCA $17.36
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- ESCA 49.82
- ADCT 39.86
- Support Level
- ESCA $14.31
- ADCT $1.56
- Resistance Level
- ESCA $16.19
- ADCT $1.75
- Average True Range (ATR)
- ESCA 0.53
- ADCT 0.11
- MACD
- ESCA -0.03
- ADCT 0.00
- Stochastic Oscillator
- ESCA 36.17
- ADCT 17.39
About ESCA Escalade Incorporated
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are North America, Europe and others out of which a substantial part of the revenue is generated from North America region.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.